Efficacy and safety of PCSK9 monoclonal antibodies: an evidence-based review and update
Author:
Affiliation:
1. Hamad Medical Corporation, Heart Hospital Pharmacy, Doha, Ad Dawhah, Qatar
2. Department of Cardiology, Hamad Medical Corporation, Al-khor Hospital, Doha, Ad Dawhah, Qatar
Publisher
Informa UK Limited
Subject
General Medicine
Link
https://www.tandfonline.com/doi/pdf/10.1080/21556660.2020.1801452
Reference137 articles.
1. Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized Controlled Trials
2. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
3. Cholesterol-Lowering Agents
4. The Evolving Future of PCSK9 Inhibitors
Cited by 16 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Targeting Allosteric Site of PCSK9 Enzyme for the Identification of Small Molecule Inhibitors: An In Silico Drug Repurposing Study;Biomedicines;2024-01-26
2. PCSK9 Inhibition in Atherosclerotic Cardiovascular Disease;Current Pharmaceutical Design;2023-09-06
3. Development of Orally Bioavailable Peptides Targeting an Intracellular Protein: From a Hit to a Clinical KRAS Inhibitor;Journal of the American Chemical Society;2023-07-18
4. The evolving landscape of PCSK9 inhibition in cancer;European Journal of Pharmacology;2023-06
5. Genetics, Safety, Cost-Effectiveness, and Accessibility of Injectable Lipid-Lowering Agents: A Narrative Review;Journal of Lipids;2023-03-08
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3